Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma

NCT04224493 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04224493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04224493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 11, 2020
Completion date
March 1, 2029
Enrollment
599 (actual)
Sites
204

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, refractory follicular lymphoma, relapsed/refractory follicular lymphoma